A handful of Houston startups were selected for a national accelerator program. Photo via Getty Images

Four Houston startups have been selected for the 2023 cohort of the MedTech Innovator’s four-month accelerator program.

Los Angeles-based MedTech Innovator, which bills itself as the world’s largest medtech accelerator, will award $800,000 in funding to winners of its competitions throughout the 2023 program. The grand prize is $350,000.

Almost 1,200 startups applied to participate in this year’s accelerator. From that group, MedTech Innovator, its corporate partners, and more than 400 judges picked nearly 200 candidates for in-person pitching and partnering events. Sixty-one startups ultimately were chosen for the 2023 cohort, which kicks off June 14 and 15.

Forty-two of the 61 startups will participate in MedTech Innovator’s corporate mentorship program, and five companies will join a plastic surgery accelerator in conjunction with the American Society for Plastic Surgeons.

MedTech Innovator says more than 500 startups have completed its accelerator program and have secured $6.8 billion in follow-on funding.

“We are proud of our stellar track record of identifying and perfecting the most innovative medtech startups in the world,” Paul Grand, CEO and founder of MedTech Innovator, says in a news release.

The four Houston companies selected for the MedTech Accelerator’s 2023 cohort are:

  • Ankr. The startup (whose name is pronounced “anchor”) provides a caregiving platform for cancer patients in the U.S. As of 2022, there were an estimated 18.1 million cancer survivors across the country. The company won The Ion’s Houston Startup Showcase in 2021.
  • NeuraStasis. The startup is developing an electrical stimulation device to delay the effects of acute ischemic stroke. This type of stroke happens when blood flow to the brain decreases. Acute ischemic stroke affects about 700,000 people in the U.S. each year. The company was selected for last year’s cohort of the UCSF Rosenman Institute’s Rosenman Innovators program.
  • Nininger Medical. The startup is working on a device for minimally invasive replacement of the tricuspid valve. Today, an estimated 1.6 million Americans experience tricuspid regurgitation. This type of heart disease occurs when the tricuspid valve’s flaps don’t close correctly. In 2021, the company received a $256,000 National Science Foundation grant.
  • Prana Thoracic. The startup is developing a tool for minimally invasive removal of lung tissue in lung cancer patients. In March, the company announced $3 million in series A funding.

Last year, three Houston companies were selected for the program. The startups — Ad Vital, Corveus Medical, and CorInnova.

Over 1,000 companies applied to participate in the 2023 MedTech Innovator Accelerator, 200 pitched in person, and 61 startups were selected. Graphic via https://medtechinnovator.org/

This week's roundup of Houston innovators includes Joanna Nathan of Prana Thoracic, Alfredo Arvide of Cloche, and Susan Davenport of the Greater Houston Partnership. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to mobile ordering — recently making headlines in Houston innovation.

Joanna Nathan, CEO, and co-founder of Prana Thoracic

Prana Thoracic, an innovative startup in the lung cancer diagnostics space, has raised its series A round of investment. Photo via LinkedIn

Joanna Nathan has been busy. It's been just under six months since the launch of her company, Prana Thoracic, a Houston health tech startup tackling lung cancer diagnostics, and the company has already secured its next round of investment funding. A medical device company developing a tool for early interception of lung cancer, the company announced last week that it closed a $3 million series A financing round.

In August, the company received a $3 million award from the Cancer Prevention & Research Institute of Texas. All of Prana Thoracic's funding is being used to develop the unique diagnostic product and the company's path to first-in-human clinical studies.

“Our technology provides a definitive answer to patients with lung nodules and allows physicians to intervene earlier in the lung cancer patient’s journey,” says Joanna Nathan, CEO, and co-founder of Prana, in a news release. “Our team is grateful to have the support of our investors and excited to leverage this financing to accelerate our technology to the bedside.” Read more.

Alfredo Arvide, co-founder and managing director of Cloche

This new restaurant technology allows for eateries to upgrade to mobile ordering for no cost. Photo courtesy of Cloche

A new mobile software platform has launched in Houston and is currently looking for restaurants interested in utilizing their technology to upgrade their eatery with mobile ordering at no cost to the restaurant.

Alfredo Arvide, co-founder and managing director of Cloche, tells InnovationMap that the idea for the platform came after the pandemic forced restaurateurs to quickly pivot to touch-free menus. Now that the consumer has adapted to scanning QR codes to view menus, the next step is to optimize ordering — something that will also help with the labor shortages that restaurants are now facing.

"Now is the time transform this industry by creating a better meal experience for the consumers, an easier job for the restaurant staff and a more efficient, more profitable business for restaurant owners," Arvide says. Read more.Read more.

Susan Davenport, senior vice president and chief economic development officer for the Greater Houston Partnership

The Greater Houston Partnership's Susan Davenport shares details on Houston House at SXSW, HETI House at CERAWeek, and taking the city on tour to spread awareness of the ecosystem. Photo via houston.org

Every year, one of the biggest tech conferences in the world convenes right down the road from Houston in downtown Austin. That's a huge opportunity for the Greater Houston Partnership to showcase and congregate Housto's tech innovators.

Susan Davenport, senior vice president and chief economic development officer for the Greater Houston Partnership, shares on the Houston Innovators Podcast how the GHP has made an effort to increase Houston's presence at SXSW over the past few years. This year, the third year for Houston House, the GHP and the Houston Energy Transition Initiative are convening over 20 Houston innovators for two days of programming.

"We want to further the development of our ecosystem," Davenport says on the podcast. "Houston is so uniquely place for this — we have such well-developed industry sectors and a customer base. ... All entrepreneurs want to showcase their products and talk about what their doing. We'll have people there to answer questions and, most importantly, invite them to Houston." Read more and listen to the episode.

Prana Thoracic, an innovative startup in the lung cancer diagnostics space, has raised its series A round of investment. Photo via LinkedIn

Houston health tech company closes $3M series A

money moves

It's been just under six months since the launch of Prana Thoracic, a Houston health tech startup tackling lung cancer diagnostics, and the company has already secured its next round of investment funding.

Prana Thoracic, a medical device company developing a tool for early interception of lung cancer, announced last week that it closed a $3 million series A financing round led by Florida-based New World Angels with participation from Johnson & Johnson Innovation – JJDC, Inc., Texas Medical Center Venture Fund, and the University City Science Center’s Phase 1 Ventures.

In August, the company received a $3 million award from the Cancer Prevention & Research Institute of Texas. All of Prana Thoracic's funding is being used to develop the unique diagnostic product and the company's path to first-in-human clinical studies.

“Our technology provides a definitive answer to patients with lung nodules and allows physicians to intervene earlier in the lung cancer patient’s journey,” says Joanna Nathan, CEO, and co-founder of Prana, in a news release. “Our team is grateful to have the support of our investors and excited to leverage this financing to accelerate our technology to the bedside.”

The company's technology is a minimally invasive, tissue-sparing nodulectomy tool that can evaluate suspicious pulmonary nodules early on in hopes of being able to catch and treat patients with lung cancer. The tool's development originated on the grounds of the Texas Medical Center in collaboration with Precision Thoracic Corp.

“Prana’s cutting-edge technology was developed on the TMC campus, and we are excited to continue to support Prana in meeting its next milestone through funding from the TMC Venture Fund. The technology they are spearheading could be a game changer in how physicians detect and treat lung cancer. Congratulations to the team on this exciting announcement,” says William McKeon, president and CEO of the Texas Medical Center, in the release.

Micheal Haimour, director of New World Angels, has joined Prana as a board member.

“We are delighted to support CEO Joanna Nathan and her team at Prana as they seek to develop solutions for the early detection and intervention of lung cancer,” he says in the release

Since the company emerged from stealth last summer, Prana has added a few feathers to its cap as a startup. In November, Nathan pitched and won first place at Ignite Healthcare Network’s annual Fire Pitch Competition. Prana was also named a finalist in the Female-Founded Businesses category of the Houston Innovation Awards. Currently, Prana is a member of the Spring 2023 cohort of the TMCi HealthTech Accelerator.

This month, TMCi is welcoming a slew of health tech and cancer innovators who will advance solutions in medicine over the next several months. Image via TMC.edu

TMC announces entrepreneurs, researchers joining its 2 health tech accelerators

coming soon

The Texas Medical Center has announced the latest cohorts of its two health tech accelerators.

The Texas Medical Center Innovation has named eight companies that are in the Spring 2023 Accelerator for HealthTech cohort. TMCi also announced 21 participants are set to join the 2023 Accelerator for Cancer Therapeutics cohort. Both programs connect the entrepreneurs and innovators to experts at TMC’s campuses to solve unmet clinical needs and reach the next business milestone.

“At TMC Innovation, we start with a promise of uniting cutting-edge innovators in science and medicine with the talent found at the Texas Medical Center," says Emily Reiser, associate director of TMC Innovation, in a news release. "Our 2023 cohort members are tackling some of the most critical issues we face today in healthcare.

"We are excited to welcome a new group of researchers and companies to the TMC Innovation Factory, and to work collaboratively with our new cohort members and our partners from across the Texas Medical Center," she continues.

Here's what 2023 can expect from these two program's cohorts.

TMCi HealthTech Accelerator

The six-month, twice annual HealthTech Accelerator — originally launched in 2014 with over 225 alumni companies — focuses on digital health and medical device startups. The spring cohort are addressing solutions across maternal medicine, mental health, diagnostics, patient experience, and artificial intelligence.

"Uniting talented professionals from across the globe provides a unique opportunity for innovation, creativity, and development in diverse areas of expertise," says Devin Dunn, head of the Accelerator for Healthtech at TMCi, in the release. "Our tailored program maximizes participants' experiences while determining the best match between these companies and Texas Medical Center’s network."

The cohort was selected following a November bootcamp that introduced potential startup members to the TMC and the Houston health care community.

The following companies will join the TMC this month:

  • Based in Roseville, Minneapolis, Bloom Standard is deploying the first self-driving pediatric ultrasound to earlier diagnose heart and lung conditions in primary care, remote and under-resourced settings.
  • San Francisco-based Ejenta automates remote monitoring and care using AI technology exclusively licensed from NASA. “Intelligent agents” learn from connected devices, claims and EMR data to monitor patients, predict health and to provide automated support for patients and automated workflow for clinicians.
  • Kintsugi, based in Berkley, California, is on a mission to see mental health more clearly by developing novel voice biomarker infrastructure to detect signs of depression and anxiety from short clips of free-form speech.
  • San Francisco-based Lana Health is modernizing patient experiences, across the care continuum with an end-to-end, scalable platform, enabling frictionless care transitions, high patient satisfaction, and better clinical outcomes.
  • Liberate Medical, from Crestwood, Kentucky, improves outcomes for mechanically ventilated patients using its breakthrough, non-invasive, respiratory muscle-protective, neurostimulation device, VentFree.
  • Limbix, headquartered in Palo Alto, has a mission to improve mental health with accessible technology.
  • Nua Surgical, from Galway, Ireland, Nua Surgical is an award-winning Irish start-up dedicated to innovating in women’s health.
  • Houston-based Prana Thoracic is developing solutions for the detection and intervention of early-stage lung cancer.

Accelerator for Cancer Therapeutics

The TMC has announced the 21 researchers and companies tapped to join the 2023 Accelerator for Cancer Therapeutics.

The nine-month program, funded by the Cancer Prevention and Research Institute of Texas in partnership with the Gulf Coast Consortia and the University of Texas Medical Branch, supports investigators and early-stage biotechnology companies with innovative solutions in cancer therapeutics. Participants will be mentored by a group of scientific, business, and innovation leaders to ultimately be positioned to apply for grants and pitch to investors and corporate partners to further the development of their innovative cancer solutions.

“For this third cohort, we focused on a strategic and extensive recruitment process, including the evaluation of 1,679 cancer research projects. From 56 applications, we selected 21 participants that will gain access to valuable resources, integrated training and mentorship to prepare for clinical trials,” says Ahmed AlRawi, program manager of Accelerator for Cancer Therapeutics, in the release. “Our 2023 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. We are excited to continue the momentum and build off the successes of our previous years.”

Forty-five participants have gone through the accelerator program since its launch in 2021, and collectively, the entrepreneurs have raised more than $90 million in funding and three projects are in the clinic.

The 2023 cohort participants are focused on a wide range of therapeutic assets, including small molecule, antibody, peptide/protein, cell therapy, and other. The 2023 cohort kicks off their nine-month program in January.

The participants include:

  1. Dr. Amit K. Tripathi – UNT-Health Science Center
  2. Dr. Darshan Gandhi (ImproveBio, LLC)
  3. Dr. Frank McKeon (Tract Pharmaceutical) – University of Houston
  4. Dr. Hemanta Baruah (Aakha Biologics)
  5. Dr. Joshua Gruber – UT-Southwestern
  6. Dr. Kyoji Tsuchikama – UT Health Science Center-Houston
  7. Dr. Maralice Conacci Sorrell – UT-Southwestern
  8. Dr. Michael Buszczak – UT-Southwestern
  9. Dr. Nadezhda (Nadia) German -Texas Tech-Lubbock
  10. Dr. Parsa Modareszadeh (HemePro Therapeutics) – UT-Dallas
  11. Dr. Robert Kruse (HydroGene Therapeutics)
  12. Dr. Xiang Zhang – Baylor College of Medicine
  13. Dr. Youngwook Won (Singular Immune, Inc.)
  14. Dr. Zhi-Ping Liu (Raphael Pharmaceutical LLC) – UT-Southwestern
  15. Dr. Jonathan Arambula (InnovoTEX Inc.)
  16. Dr. Isaac Chan – UT-Southwestern
  17. Dr. Olga Granaturova (Ruptakine Inc.) – UT Health Science Center-Houston
  18. Dr. Jim Song (Tranquility Biodesign) – Texas A&M-College Station
  19. Dr. Rosa Selenia Guerra-Resendez (Quetzal Bio, LLC) – Rice University
  20. Dr. Cassian Yee (Mongoose Bio, LLC) – UT-MD Anderson Cancer Center
  21. Dr. Manjeet Rao (Niragen, Inc.) – UT Health Science Center-San Antonio


Three female-founded health tech startups won awards at this year's Ignite Healthcare's Fire Pitch Competition. Photo courtesy of Ignite

Houston health tech startup wins female-focused pitch competition

women in health care

For the fourth year, a Houston-based, female-focused health tech organization has spotlighted the industry's emerging technology entrepreneurs.

Earlier this month, Ignite Healthcare Network’s Accelerator Program hosted its seven women-led digital health startup finalists, narrowed down from over 330 startups, at its annual Fire Pitch Competition. The nonprofit is led by a group of women executives committed to shaping the future of health care.

“The fourth year of Ignite Health’s Accelerator Program has proved to attract more and more women founders of digital tech and med device startups from around the world,” says Ayse McCracken, Ignite's founder, in a news release.

According to McCracken, 22 applicants made it into the program, which launched earlier this year. A group of judges narrowed down that group to seven finalists, before announcing the top three companies for the competition.

Joanna Nathan, CEO of Houston-based Prana Thoracic, won the top award for her company. Stephanie Gravenor, founder of Denver-based Medecipher, and Liane Clamen, founder of Chestnut Hill, Massachusetts-based Adaptilens, won second and third, respectively.

The event doled out over $500,000 in total. Jay Goss, general partner of Wavemaker Three-Sixty Health, announced $100,000 investments into four finalists' companies. The finalists receiving this award are:

  • Pamela Bonnett, CEO of Denver-based Ultrasound AI
  • Christine Lum Lung, co-founder and CEO of Fort Collins, Colorado-based Origin Healthcare
  • Pamela Singh, co-founder and CEO of Houston-based CaseCTRL
  • Stephanie Gravenor, founder and CEO of Denver-based Medecipher

The partner organizations participating in this year's accelerator and event included Houston Methodist, Memorial Hermann Health System, Texas Children’s Hospital, Texas Children’s Pediatrics, The Menninger Clinic, HCA, Kindred Healthcare, Aetna, Texas Health Resources, Cook Children’s Hospital, TMC, Golden Seeds, Wavemaker 360 Health, Portfolia, Prosalus, 7Wire, Texas Halo Fund, Unity Point Ventures, and others.

“We are grateful for the support and generosity of our sponsors for helping to make this event possible,” says Cheryl Stavins, Ignite board member and co-chair of the event, in the news release. “Their support and involvement continue to ignite our mission and passion to ensure the success and recognition of women entrepreneurs in healthcare.”

Earlier in the day, Ignite Health hosted a new event called “Women Shaping the Future of Healthcare Luncheon." Eighty female executives, investors, founders, and community leaders gathered to hear from three of Ignite Health’s alumni founders: Somer Baburek, CEO of Hera Biotech, Dr. Liz Clayborne, CEO of Nasaclip, and Amanda Gorman, chief clinical officer of Nest Collaborative.

Eight of the 10 most-promising life science startups named at BioHouston and the Rice Alliance's event are based in Houston. Photo courtesy of Rice Alliance

Houston startups named most promising in the life science space at annual event

ones to watch

For the second time this year, Houston life science leaders and startup founders gathered to discuss the future of health care in Houston.

The annual Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship was usually held during the fall before the pandemic pushed it off schedule. In February, the two organizations hosted the previous forum, but as of this month, the annual event is back on track.

The day included panels and networking, plus over 50 companies — about half of which are based in Houston — pitched their solutions across medical device, therapeutics, pharmaceuticals, and more to the crowd.

Houston-based Bairitone Health won the Michael E. DeBakey Memorial Life Science Award, established by BioHouston in honor of the groundbreaking Houston cardiovascular surgeon. The company is creating a wearable technology that takes a more innovative approach to sleep apnea and snoring with its SOMNAR platform that detects tissue-born sounds, identifies obstructions, and more. The award was presented by Ann Tanabe, CEO of BioHouston.

Ann Tanabe, CEO of BioHouston, presented the DeBakey Award to Houston-based Bairitone Health. Photo courtesy of Rice Alliance

For the first time, the event also named a people's choice award winner, as voted on by the audience members. Baritone Health also claimed the prize.

At the conclusion of the event, the Rice Alliance and BioHouston named the 10 most promising life science companies selected by investors and presented by the Greater Houston Partnership. This year's selection included the following companies, in alphabetical order.

Autonomize

Austin-based Autonomizeunlocks data and context to enable human health outcomes

bEHR Health Systems

New Orleans-based bEHR Health Systemsdelivers, medical, lifestyle, and social solutions to health for African Americans.

EMPIRI

EMPIRI, based in Houston, is revolutionizing cancer care with a novel technology that accurately predicts each cancer patient's treatment responses empirically, enabling doctors to make the optimal treatment selection for each cancer patient.

InformAI

Houston-based InformAI develops AI-based medical image diagnostic tools and uses large dataset synthesis to develop clinical outcome predictors for physicians, hospitals, and medical imaging/medical device companies

March Biosciences 

Houston-based March Biosciences is impacting the most challenging lymphoma and leukemia.

MRG Health-SmartCare360

MRG Health-SmartCare360, based in Houston, is a determinate of health and disease specific virtual care management technology and services company that improves patient access to care and clinical outcomes for people suffering from one or more chronic disease.

Prana Thoracic

Prana Thoracic, founded in Houston out of JLABS at TMC, is a medical device startup that's innovating for the future of early intervention in lung cancer.

Steradian Technologies

Another med device startup based in Houston,Steradian Technologiesemploys deep-photonics technology to diagnose respiratory diseases in seconds, all for the price of a latte.

TYBR Health

Houston-based TYBR Health makes a hydrogel that protects tendons from scarring after surgery and improves patient outcomes.

Voythos

Voythos, based in Houston, is making medical records work for today's healthcare.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston hospitals recognized as best in state, nation in annual report

better than all the rest

Houston’s University of Texas MD Anderson Cancer Center has retained its U.S. News & World Report crown as the best cancer hospital in the U.S.

In the same ranking, Houston Methodist Hospital once again came out on top as the best hospital in Texas. Last year, the hospital shared the top spot. Baylor St. Luke’s Medical Center ranked No. 4, followed by No. 5 Memorial Hermann Hospital.

The accolades appear in U.S. News2024-25 ranking of the country’s best hospitals. Each hospital also ranked among various specialties, such as orthopedics; cardiology, heart, and vascular surgery; cancer; and neurology and neurosurgery.

Since U.S. News introduced its annual hospital survey in 1990, MD Anderson has been ranked one of the two best U.S. hospitals for cancer care. It has maintained its No. 1 ranking for 10 consecutive years.

“At MD Anderson, our mission is clear: to end cancer,” Dr. Peter WT Pisters, president of MD Anderson, says in a news release. “This ranking reflects our relentless commitment to excellence in patient care, research, prevention, and education.”

MD Anderson also ranked highly in three specialties:

  • No. 2 for ear, nose, and throat.
  • No. 9 for urology.
  • No. 14 for gastroenterology and GI surgery.

“The consistent top national recognitions [that] MD Anderson receives for delivering compassionate, evidence-based care is a testament to our dedication to those we serve,” Pisters says.

Elsewhere at the Texas Medical Center, Houston Methodist Hospital was named the No. 1 hospital in Texas for the 13th year in a row. Also, it was lauded as one of the country’s 20 best hospitals for the eighth time.

Along with the general ranking, Houston Methodist Hospital scored high marks in 10 specialties. These include diabetes and endocrinology (No. 6), gastroenterology and GI surgery (No. 7), and pulmonology and lung surgery (No. 8).

Meanwhile, four Houston Methodist community hospitals ranked well in Texas:

  • Houston Methodist The Woodlands Hospital (No. 8).
  • Houston Methodist Sugar Land Hospital (No. 9).
  • Houston Methodist Baytown Hospital (tied at No. 18).
  • Houston Methodist Willowbrook Hospital (tied at No. 23).

New app with tips for solo women travelers takes flight from Texas

explore mode activated

We all have that one friend whose office seems to be the nearest airport gate. We go to them for travel advice and hit save on their latest post for that hole-in-the-wall restaurant that had the best local food. That type of advice — especially between women — is indispensable for solo travelers, and now a new travel app based in Austin is helping organize it on a new platform without the social media noise.

Solo travel has gained a lot of momentum in the past few years, and it’s no longer just something one does during a gap year before or after college. It’s become the preferred way to travel for many, and women are at the forefront.

According to Condor Ferries, 72 percent of American women like to take solo trips, and the term “female solo travel” has increased 62 percent over the past three years across all search engines. What if there was a place where women solo travelers could get recommendations and travel itineraries created by other solo women travelers?

This concept is the backbone of Airheart, which aims to revolutionize the travel industry by offering a safe space for solo female travelers to find itineraries and travel guides that were crafted with them in mind.

"Traveling solo as a woman is an empowering act of independence," said Airheart founder Lindsey Renken in a press release. "At Airheart, we celebrate and support this journey, helping women discover new places, connections, and strengths."

The platform includes integrated planning tools, interactive maps, itineraries, and video tips all conveniently located in one place and customizable to the traveler’s preference. Once a user creates an account and accesses the site, the navigation is pretty straightforward.

There’s an explore option at the top of the home screen showcasing all the travel guides available for purchase within the platform, with destinations all over the world. At the moment, most are within the US, Mexico, Western Europe, and Asia. Once the user chooses a guide, a sidebar populates with a list of recommendations or a day-by-day itinerary. The right side of the screen is a map with all the pinned recommendations for easy navigating.

For those wanting to travel more within Texas this summer, Airheart offers a few destinations with a wide range of activities:

  • Big Bend/West Texas: For nature lovers, explore the beautiful mountain desert region of West Texas with a comprehensive guide that includes tips on how to get there and how to choose the best accommodation for your trip — something that becomes more complex in such a remote place.
  • Glen Rose: Escape to this charming small town just an hour-and-a-half Southwest of Dallas-Fort Worth, that is perfect for a weekend getaway full of outdoor adventures. These recommendations come from a local.
  • Fredericksburg: Indulge in the best wineries and restaurants that Central Texas has to offer with an itinerary crafted by a Texas native. This one is ideal for a quick day trip or a fun girls’ weekend.

Airheart, named after the pioneering aviator Amelia Earhart, is also focused on empowering female travel creators by allowing them to act as a type of modern travel agent. They can monetize both new and existing travel content by creating these guides and itineraries, while reaching a new audience on the platform.

“As an avid traveler, I’m always looking for something like this created by expert travelers. I can’t wait to be a seller and consumer,” said Tanna Wasilchak who contributed guides for Waco, Glen Rose, and Georgetown. “Solo traveling as a female can be intimidating at first, but it’s one of the most rewarding experiences I’ve ever had. Airheart is going to be such a game changer for this community.”

Perhaps the only downside for now is that Airheart is limited in what it can offer to its users with only 22 guides published on the site. However, the features and community-based aspect give the platform the potential to stand out in an otherwise saturated market. Guides ($29 each before taxes and fees) are available for users to browse and purchase at airheart.com.

------

This article originally ran on CultureMap.

Houston startup adviser on navigating SAFE, convertible notes in funding rounds

guest column

As both a founder and occasional early-stage investor in the Houston ecosystem, I've seen firsthand the opportunities and challenges surrounding seed funding for local startups. This critical first fundraising round sets the trajectory, but navigating the landscape can be tricky, especially for first time founders who may not be familiar with the lingo.

One key dynamic is choosing the right deal structure — SAFEs (Simple Agreement for Future Equity) vs. convertible notes are the most common vehicles early stage startups use to raise capital and are far more founder-friendly than a priced round.

Let's start first with what the have in common:

  • Both allow you to defer setting a valuation for your company until a later (likely priced) round, which is useful in early stages or pre-revenue companies
  • Both are cheaper and faster to execute than a priced round, which cash-strapped early stage founders like
  • Both can have terms like valuation cap, discount, conversion event, and pro rata rights.
  • Both are less attractive to investors seeking immediate equity (especially important if starting the QSBS clock is part of your investors strategy or if the investor is newer to startup investing)
  • Both can create messy cap tables and the potential for a lot of dilution for the founders (and investors) if they are used for multiple raises (especially with different terms)

While as you can see they have similarities, they have some important differences. Let's dig in on these next:

SAFEs:

  • Created by Y Combinator in 2013, the intent was to create a simplified, founder friendly agreement as an alternative to the convertible note
  • Is an agreement for future equity for the investor at a conversion event (priced round or liquidation event) which converts automatically.
  • It's not a debt instrument and does not accrue interest or have a maturity date.
  • Generally have much lower upfront legal costs and faster to execute

Convertible Notes:

  • A debt agreement that converts to equity at a later date (or conversion event like a priced round)
  • Accrues interest (usually 2 to 8 percent) and has a maturity date by which the note must either be repaid or convert to equity. If you reach your maturity date before raising a qualifying round, you can often renegotiate to extend the maturity date or convert the note, though be prepared to agree to higher interest rates, additional warrants, or more favorable conversion terms.
  • More complex and take longer to finalize due to non-standard terms resulting in higher legal and administrative costs

It's worth reiterating that in both cases, raising multiple rounds can lead to headaches in the form of complex cap tables, lots of dilution, and higher legal expenses to determine conversion terms. If your rounds have different terms on discounts and valuation caps (likely) it can cause confusion around equity and cap table structure, and leave you (the founder) not sure how much equity you will have until the conversion occurs.

In my last startup, our legal counsel — one of the big dogs in this space for what it's worth — strongly advised us to only do one SAFE round to prevent this.

Why do some investors tend to prefer convertible notes?

There are a few reasons why some investors, particularly angel investors from developing startup ecosystems (like Houston), prefer convertible notes to SAFEs.

  • Because they are structured as debt, note holders have a higher priority than equity investors in recovering their investment if the company fails or is liquidated. This means they would get paid after other creditors (like loans or credit cards) but before equity investors, increasing the likelihood of getting some of their money back.
  • The interest terms protect investors if the founder takes a long time to raise a priced funding round. As time passes, interest accumulates, increasing the investor's potential return. This usually results in the investor receiving a larger equity stake when the note converts. However, if the investor chooses to call in the note instead, the accrued interest would increase the amount of money owed, similar to a traditional loan
  • More defined conversion triggers (including a maturity date) gives investors more control and transparency on when and how their investment will convert.
  • Can negotiate more favorable terms than the standard SAFE agreement, including having both a valuation cap and a discount (uncommon on a SAFE, which usually only has one or the other), interest rates, and amendment clauses to protect them from term revisions on earlier investors by future investors (called a cram-down), etc.
We'll go over what the various terms in these agreements are and what to look out for in a future article

How to choose:

  • Consider your startup's stage and valuation certainty — really uncertain or super early? Either of these instruments are preferable to a priced round as you can defer the valuation discussion
  • Assess investor preferences in your network — often the deciding factor if you don't have a lot of leverage; most local angels prefer c-notes because they see them as less risky though SAFEs are becoming more common with investors in tech hubs like Silicon Valley
  • Evaluate your timeline and budget for legal costs — as I mentioned, SAFEs are way less expensive to execute (though still be prepared to spend some cash).
  • Align the vehicle with your specific goals and growth trajectory

There's no one-size-fits-all solution, so it's crucial to weigh these factors carefully.

The meanings of these round terms like "seed" are flexible, and the average seed funding amount has increased significantly over the past decade, reaching $3.5 million as of January 2024. This trend underscores the importance of choosing the right funding vehicle and approach.

Looking ahead, I'm bullish on Houston's growing startup ecosystem flourishing further. Expect more capital formation from recycled wins, especially once recently minted unicorns like High Radius, Cart.com, Solugen, and Axiom Space exit and infuse the ecosystem with fresh and hungry angels, new platforms beyond traditional venture models, and evolving founder demographics bringing fresh perspectives.

------

Adrianne Stone is the principal product manager at Big Cartel and the founder of Bayou City Startups, a monthly happy hour organizer. This article original ran on LinkedIn.